Fernández, I.S., Cuevas, P., Angulo, J., López-Navajas, P., Canales-Mayordomo, A., Lozano, R.M., Valverde, S., Jiménez-Barbero, J., Romero, A. and Giménez-Gallego, G. (2010) Gentisic acid, a compound associated with plant defence and a metabolite of aspirin, heads a new class of in vivo FGF inhibitor. The Journal of Biological Chemistry, 285, 1714-1729.
http://dx.doi.org/10.1074/jbc.M109.064618

has been cited by the following article:

• TITLE: Dobesilate for dry age-related macular degeneration

  AUTHORS: Pedro Cuevas, Luis A. Outeiriño, Carlos Azanza, Javier Angulo, Guillermo Giménez-Gallego

  KEYWORDS: Dry Age-Related Macular Degeneration; Fibroblast Growth Factor Inhibition; Intravitreal Dobesilate

  JOURNAL NAME: Journal of Biomedical Science and Engineering, Vol.6 No.10B, October 15, 2013

  ABSTRACT: We have evaluated the effects of intravitreal dobesilate, a synthetic fibroblast growth factor inhibitor, in patients with dry age-related macular degeneration, an inflammatory-related retinal disease without available treatment up to date. 36 eyes from 36 patients with dry age-related macular degeneration were treated with a single intravitreal dobesilate injection. The end points were the improvement from baseline visual acuity and normalization of retinal histology at one month. Intravitreal dobesilate injection resulted in a significant improvement in functional and anatomical outcomes at one month after injection. Our results suggest that intravitreal dobesilate may increase the chance of visual acuity gain in dry age-related macular degeneration, even in cases with initial low vision. This study supports the findings of previously published case reports, regarding the short-term improvement in visual acuity by intravitreal dobesilate injection in different degenerative retinal diseases.